Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports. Video provided by Reuters
Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics. Investment...Show More Summary
(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.
Biotech giant Celgene is acquiring Juno Therapeutics for $9 billion. Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy, which harnesses the body's immune system to go after certain blood cancers. It's part of a new field of cancer therapies that. Show More Summary
(Reuters) - Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as it moves to cement its position as a key player in a new range of cancer therapies.
Biopharmaceutical firm Celgene will pay about $9 billion to acquire the shares of Juno Therapeutics that it doesn't already hold.
French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments, in a deal worth $9 billion. Both stocks are up bigShow More Summary
Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion. It's be the second in 2018 for the biotech giant, which has been under pressure from investors. The highly personalized...Show More Summary
Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that use the body's...Show More Summary
Shares of Juno Therapeutics are up more than 50% in early trading on Wednesday following a Wall Street Journal report Tuesday evening that biotech giant Celgene is in talks to buy the cancer drugmaker. Juno is developing a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor). Show More Summary
Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors. Juno is known for...Show More Summary
ZURICH (Reuters) - Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.
Following the deaths of five patients, Juno Therapeutics has decided to pull the plug on an experimental cancer treatment that boosts the power of a patient’s immune cells. The news comes just days after the company’s rival, Kite Pharma, announced its success with a similar method, showing there’s still hope for this… Read more...
(Reuters) - Juno Therapeutics Inc on Wednesday said it decided to shut down development of an experimental leukemia treatment from a highly promising new class of immunotherapy following an investigation into toxicity that led to a handful of patient deaths.
Leaders from Fred Hutch, Seattle Cancer Care Alliance and Juno Therapeutics will speak on immunotherapy's roots in Seattle, new clinical trials and the prospects for developing new cures for cancer during a Dec. 12 scientific symposium to celebrate the opening of the first-of-its-kind clinic